Breaking | China says it has “successfully” developed the coronavirus vaccine and prepares for its large-scale production

Watch US vaccines trial video below 
The official statement at the Ministry of Defense of the People's Republic of China
The official statement at the Ministry of Defense of the People’s Republic of China

The Military Academy of Medical Sciences of the People’s Republic of China said on Tuesday that it had “successfully” developed the recombinant coronavirus vaccine, and noted that it is being prepared for “large-scale” production , according to a statement issued by the Ministry of Defend this country.

The vaccine has been approved for the start of human clinical studies, in accordance with international standards and national regulations, the agency says.

Details in the Chinese clinical trial registration database show that a “Phase 1” test that will examine whether the experimental vaccine is safe in humans aims to recruit 108 healthy people to participate in the process between March 16. and on December 31.

The trial will be conducted by the Military Academy of Medical Sciences and biotech firm CanSino Biologics RIC, the Reuters agency reported .

Dr. Chen Wei led the research team
Dr. Chen Wei led the research team

This vaccine candidate , known as mRNA-1273, was developed by the NIH and the Massachusetts-based biotech company Moderna Inc. There is no chance of participants being infected because the vaccines do not contain the coronavirus itself.

This is explained in a paper from the University of Cambridge: “Unlike a normal vaccine, RNA vaccines work by introducing a sequence of mRNA (the molecule that tells cells what to build) that is encoded for a specific antigen of the disease, once produced within the body, the immune system recognizes the antigen, preparing to fight the real thing. “

Translated from and More @ Source: China dice haber desarrollado “con éxito” la vacuna contra el coronavirus y se prepara para su producción a gran escala – Infobae

CORONAVIRUS Scientists at the Kaiser Permanente Washington Research Institute began the first-stage study of a potential COVID-19 vaccine on volunteer, Jennifer Haller, in Seattle, Monday, March 16.


A clinical trial evaluating a vaccine designed to protect against the new coronavirus began Monday.

The National Institutes of Health is funding the trial, which is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle. Public health officials say it will take a year to 18 months to fully validate any potential vaccine.

Testings begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc.There’s no chance participants could get infected from the shots, because they don’t contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests. See:
Translate »